Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
Research ArticlePractical Protocol Tips

Amyloid Imaging

Jessica Williams
Journal of Nuclear Medicine Technology December 2018, 46 (4) 341-342; DOI: https://doi.org/10.2967/jnmt.118.222190
Jessica Williams
CNMT, RT(N), FSNMMI-TS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Rationale

Amyloid imaging is performed to assist in the detection of β-amyloid plaques. Although these plaques are believed to be one of the causes of cognitive impairment (CI), a positive scan does not establish a diagnosis of Alzheimer disease or other cognitive disorder.

RadiopharmaceuticalRecommended doseUptake timeAcquisition time
18F-florbetapir10 mCi (370 MBq)30–50 min10 min
18F-flutemetamol5 mCi (185 MBq)60–120 min10–20 min
18F-florbetaben8.1 mCi (300 MBq)45–130 min15–20 min
Standard Acquisition Protocol
Camera typePET or PET/CT
Energy peak511
Attenuation correctionPET: cesium or germanium  sources, PET/CT: CT acquisition
Patient positionSupine, arms down
Acquisition type3-dimensional
Time/bed positionSee radiopharmaceutical
Bed position1
RadiopharmaceuticalDisplay parameter
18F-florbetapirMaximum intensity of the display  scale should be set to the  brightest region of overall  brain uptake
18F-flutemetamolScale intensity should be set to  90% in the pons region
18F-florbetabenThe white matter maximum  should be the reference

Clinical Indications

  • Assessment of progressive or persistent unexplained mild CI.

  • Evaluation of patients with known, progressive dementia and atypically early age of onset.

  • Evaluation of patients fitting the core clinical criteria for possible diagnosis of Alzheimer disease, but the clinical presentation is either atypical or etiologically mixed.

Contraindications/Inappropriate Use

Pregnancy and breastfeeding are contraindicated but are not absolute contraindications as there are no known effects. Instructions should be provided to the patient for breast feeding and should follow the institution's policies. This scan should only be performed on pregnant women if there is a clear clinical benefit.

According to Society of Nuclear Medicine and Molecular Imaging standards and European Association of Nuclear Medicine practice guidelines, there are times when use of amyloid imaging can be considered inappropriate.

  • Evaluation of dementia severity.

  • Assessment of asymptomatic individuals with family history.

  • Assessment of asymptomatic individuals who carry APOE-ε 4 genotype.

  • Evaluation of asymptomatic individuals.

  • Nonmedical use such as employment screening and legal.

  • Evaluation of individuals with cognitive complaint that has not been confirmed.

  • Assessment of individuals with core criteria for Alzheimer disease with typical age of onset.

  • In lieu of genotyping for suspected autosomal dominant mutation carriers.

Patient Preparation/Education

  • If the patient is of childbearing age, a pregnancy test should be performed.

  • The patient may eat and take any necessary medications.

  • History should be obtained to include symptoms, current medications, relevant personal history, and recent imaging procedures.

Patient education should include careful explanation of the procedure. It may be necessary to explain the procedure multiple times or in different ways as the patient may have severe CI. The patient may need constant reminders of the need for his or her cooperation. It is often helpful to have a family member or guardian accompany the patient. Some patients may not be able to cooperate with instructions and may need sedation. In that case, institutional guidelines should be followed.

Protocol/Acquisition Instructions

There are currently 3 Food and Drug Administration–approved radiopharmaceuticals available in the Unites States: 18F-florbetapir, 18F-flutemetamol, and 18F-florbetaben. Doses, uptake times, and acquisition times will vary dependent on which radiopharmaceutical is used.

The patient is interviewed, an intravenous catheter is placed, and the patient is injected with a bolus injection via the catheter with 1 of the 3 radiopharmaceuticals. The injection is immediately followed by 5–15 mL of 0.9% sterile sodium chloride to ensure dose delivery. Once the radiopharmaceutical is injected, the catheter can be removed, and the patient should relax during the uptake time.

After waiting the allotted uptake time, the patient should be instructed to empty his or her bladder, for comfort while imaging takes place. The patient should be positioned supine on the imaging couch with the head in a head holder. The whole of the brain should be in the field of view. If possible, extreme extension or flexion of the neck should be avoided. The patient should be made as comfortable as possible with the head secured by flexible head restraints.

Images should be acquired in 3-dimensional data acquisition mode with the appropriate data corrections.

Image Processing

  • Image reconstruction should incorporate attenuation correction with the transaxial pixel sizes between 2 and 3 mm and slice thickness between 2 and 4 mm.

  • A minimum of 16-bit pixels for PET display is necessary to provide an adequate value range.

  • PET images should be displayed in the transaxial orientation using gray scale or inverse gray scale. Color scale may be used and is dependent on the recommendation of the manufacturer.

  • Image size should be optimized to evaluate the gray–white matter.

REFERENCES

    1. Farrell MB
    1. Farrell MB,
    2. Mantel ES,
    3. Basso DA,
    4. et al.
    The central nervous system: PET—amyloid brain imaging. In: Farrell MB, ed. Quick Reference Protocol Manual for Nuclear Medicine Technologist. Reston, VA: Society of Nuclear Medicine and Molecular Imaging; 2014:133–134.
  1. Florbetapir F18 [package insert]. Indianapolis, IN: Eli Lily and Company; 2013.
  2. Flutametamol F18 [package insert]. Arlington Heights, IL: GE Healthcare; 2017.
  3. Florbetaben F18 [package insert]. Dulles, VA: Piramal Imaging; 2014.
    1. Minoshima S,
    2. Drzezga AE,
    3. Barthel H,
    4. et al
    . SNMMI procedure standard/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med. 2016;57:1316–1322.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 46 (4)
Journal of Nuclear Medicine Technology
Vol. 46, Issue 4
December 1, 2018
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Amyloid Imaging
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
Amyloid Imaging
Jessica Williams
Journal of Nuclear Medicine Technology Dec 2018, 46 (4) 341-342; DOI: 10.2967/jnmt.118.222190

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Amyloid Imaging
Jessica Williams
Journal of Nuclear Medicine Technology Dec 2018, 46 (4) 341-342; DOI: 10.2967/jnmt.118.222190
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • A Year in Review
  • Google Scholar

More in this TOC Section

  • 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy
  • 223Ra-Dichloride Therapy
  • 18F-FDG PET/CT Brain Imaging
Show more Practical Protocol Tips

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire